‹ All Posts
FnO Tattva

10th Nov · SEBI-Registered Analyst

TORRENT PHARMA

TORNTPHARM
reported a 16 per cent year-on-year (Y-o-Y) rise in consolidated net profit for the September quarter (Q2FY26) to Rs 591 crore, up from Rs 453 crore in the same period last year, supported by robust sales across territories. The company’s revenue from operations rose 14 per cent Y-o-Y to Rs 3,302 crore in Q2FY26 from Rs 2,889 crore in Q2FY25.

#WatchOutFor#StockInNews#TechnicalViews#Today’sTradingSetup#Miscellaneous
1,056 likes·18 comments